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AbstrACt
Introduction The HIV pandemic continues to evolve with 
young women being the most vulnerable group to acquire 
infection. The presence of sexually transmitted infections 
(STIs) further enhances HIV susceptibility and also leads 
to long-term complications such as infertility and cervical 
cancer. The female condom is a self-initiated method for 
STI and HIV prevention but there are controversies on its 
effects. We aim to assess the effectiveness, safety and 
acceptability of the use of female condoms for prevention 
of STI and HIV acquisition among women.
Methods and analysis We will search Cochrane Central 
Register of Controlled Trials, PubMed, EMBASE, Scopus, 
WHO International Clinical Trials Registry and reference 
lists of relevant publications for potentially eligible 
studies. We will screen search outputs, select eligible 
studies, extract data and assess risk of bias in duplicate; 
resolving discrepancies through discussion and consensus 
or arbitration. We will combine data from clinically 
homogenous studies in a fixed effect meta-analysis and 
assess the certainty of the evidence using the method for 
Grading of Recommendations Assessment, Development 
and Evaluation. We registered the planned systematic 
review with the International Prospective Register of 
Systematic Reviews (PROSPERO) in March 2018 and 
will finalise the search strategy in August 2018; conduct 
the searches and select eligible studies between August 
and October 2018; and collect data, conduct statistical 
analyses and prepare and submit the manuscript for 
consideration by a peer-reviewed journal between 
November 2018 and April 2019.
Ethics and dissemination We will use publicly available 
data; hence no formal ethical approval is required for this 
review. We will disseminate the findings of this review 
through conference presentations and publication in an 
open-access peer-reviewed journal.
PrOsPErO registration number CRD42018090710.
IntrOduCtIOn 
The disease burden resulting from unsafe sex, 
including HIV infection and other sexually 
transmitted infections (STIs), has profoundly 
impacted low-income and middle-income 
regions, especially Sub-Saharan Africa.1 The 
HIV pandemic continues to evolve in both 
magnitude and diversity, with over 40 million 
infections worldwide, with young women 
aged 15–24 being 2.5 times more likely to be 
infected than young men.2 In many cases, STIs 
go undiagnosed and eventually lead to long-
term complications such as infertility and 
cervical cancer. In addition, the presence of 
an STI enhances HIV susceptibility.3–5 Several 
interventions exist for the prevention of HIV 
and STIs such as the male condom. Although 
male condoms are effective in reducing HIV 
and STIs transmission,6 the subordinate status 
of women in many countries, especially in 
Sub-Saharan Africa, makes negotiating male 
condom use with partners especially diffi-
cult.7 8 Hence, women remain particularly 
vulnerable to HIV infection and other STIs 
like gonorrhoea, chlamydia, syphilis, human 
papilloma virus (HPV) and herpes simplex 
virus (HSV) infections. There is evidence that 
increasing the availability of multiple contra-
ceptive methods for women is associated with 
increased contraceptive uptake, lower preg-
nancy rates and fewer STIs.9 Furthermore, 
the contraceptive needs and preferences 
of women have been found to change over 
the course of their reproductive life, and it 
strengths and limitations of this study
 ► We will conduct a comprehensive search for poten-
tially eligible, completed and ongoing trials which
would ensure that we obtain an unbiased summary
of intervention effects.
 ► This review will include non-randomised trials which 
are more prone to bias than randomised trials.
However, to minimise the effect of the bias, we will
perform subgroup analyses by study design.
 ► The Grading of Recommendations Assessment,
Development and Evaluation approach will be used
to assess the certainty of the evidence.
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is imperative that women have a wide variety of options 
available to encourage them to use their contraceptive of 
choice.9 There are several methods of contraception that 
exist for women such as female sterilisation, long-acting 
hormonal contraceptives, short-acting hormonal contra-
ceptives, copper intrauterine devices, barrier methods 
and natural method.10 However, the female condom, 
which is a barrier method of contraception, is the only 
female-initiated contraceptive method that offers dual 
protection against both pregnancy and STIs. In fact, 
there is evidence suggesting that it may be as effective as 
the male condom though this conclusion has not been 
demonstrated.11 12
Introduced over two decades ago, the female condom 
offers the possibility of an alternative to male condoms.12 
Several types of materials can be used to make female 
condoms, including polyurethanes, synthetic nitrile 
rubber latex, natural rubber latex and silicon.13 Gener-
ally, the structure of the female condom consists of a 
sheath that lines the vagina and may extend to cover the 
external genitalia. At the closed end of the sheath, a flex-
ible ring of foam sponge is inserted into the vagina to 
hold the female condom in place. These internal reten-
tion features also help to facilitate insertion of the female 
condom into the vagina. At the other open end of the 
sheath, there is a ring or frame that stays outside the vulva 
at the entrance to the vagina. This ring or frame prevents 
the sheath bunching up inside the vagina and also facil-
itates removal of the condom. Some female condoms 
such as the Pheonurse are prelubricated and others like 
the Cupid are scented.13 14 The first-generation female 
condom, available since 1993, was made out of polyure-
thane. However, it has been progressively replaced by 
newer female condoms, designed to lower unit cost and/
or increase acceptability. Clinical studies evaluating the 
efficacy, safety and acceptability of these new designs are 
ongoing.15–18
In comparison with the male condom, the female 
condom is said to offer additional coverage to both part-
ners and is not weakened by the use of oil-based lubricants. 
Furthermore, no serious local side effects or allergies have 
been reported. However, this non-systemic contraceptive 
method is not without limitations. It is known to be rela-
tively more expensive, with mechanical problems which 
could include breakage, slippage, invagination and misdi-
rection among others.19 20 These limitations are increas-
ingly being addressed by the designing and manufacture 
of newer forms of the female condom, with emphasis on 
proper and frequent use of existing ones.13 20
Research has been undertaken to determine the feasi-
bility of reusing the female condom.21 A consultation 
convened by the WHO in January 2002 addressed certain 
considerations regarding the reuse of female condom.22 
They concluded that although the use of a new female 
condom during each act of sexual intercourse should 
be recommended, the female condom can be reused 
in couples not at risk of pregnancy, STIs or HIV infec-
tion, but with careful attention to a disinfection, washing, 
drying and relubrication procedure. Research on the 
structural integrity of the female condom shows that 
it is maintained after five uses.23 However, additional 
research on the effectiveness of female condom reuse is 
still ongoing with newer designs of the female condom.13
There is evidence that condom use results in up to 
80% reduction in the incidence of HIV. However, these 
estimates generally refer to the efficacy of the male 
condom.6 24 25 With the advent of newer forms of the 
female condom, many randomised controlled studies 
have examined the effectiveness and acceptability of 
female condoms in preventing HIV and other STIs.15–18 
Additionally, stereotypes and strong opinions that tend 
to hamper the acceptance of female condoms exist. 
These in turn may hinder their correct and consistent 
use, an aspect that determines the effectiveness of this 
barrier method in preventing HIV. In this review, we 
seek to examine the evidence from both randomised and 
non-randomised trials, on the effect of female condom use 
on the incidence of HIV and other STIs among women. 
We also plan to explore the side effects and acceptability 
of female condoms.
MEthOds And AnAlysIs
Patient and public involvement
Patients were not involved in the design of this study. 
However, the development of the research question and 
outcome measures were informed by patient’s priorities, 
experience and preferences as reported in the litera-
ture supporting this review. The findings of this review 
will provide patients and policy-makers with the evidence 
on the efficacy and safety of existing and newer types of 
female condoms.
Criteria for considering studies for this review
We will include randomised and non-randomised 
trials that enrolled HIV negative and/or HIV positive 
women, engaged in heterosexual activity in any setting, 
with no clinical or laboratory-confirmed signs of STIs.
In addition, eligible trials would be those that compared 
the female condom to no treatment or other barrier 
methods for HIV prevention, for example, male condom, 
microbicides, diaphragm, vaginal sponges and cervical 
caps.
Finally, eligible studies need to report at least one of 
our primary or secondary outcomes of interest. Our 
primary outcomes for this review include acquisition of 
HIV (determined by a serological test) or STIs (including, 
but not limited to chlamydia, gonorrhoea, syphilis, HSV, 
trichomoniasis, candidiasis, lymphogranuloma vene-
reum, HPV and bacterial vaginosis). Eligible studies need 
to determine STI status by microscopy and/or culture of 
urogenital specimens and vesicle fluid (when possible) 
for the causal agents. We will also consider nucleic acid 
amplification tests, if reported. Cytological pap testing 
used to determine human papillomavirus infection, 
and microscopy of Gram stained genital smear used to 
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detect bacterial vaginosis will be acceptable methods of 
determining status. We will also include studies in which 
STIs were diagnosed clinically, and subgroup analyse by 
method of diagnosis (clinical vs laboratory).
Our secondary outcomes will include acceptability and 
adverse events of female condom use. Measures of accept-
ability may include scales to grade acceptability and where 
possible, these will be standardised to allow for quanti-
tative comparison across trials. If this is not possible, 
then we will provide a narrative synthesis. Adverse events 
may include difficulties in insertion and removal of the 
condom leading to inconsistent use, breakage and slip-
page of condom, decreased pleasure and penetration 
difficulties during intercourse, genital ulcerations during 
intercourse and any other adverse events reported in the 
trials.
search methods for identification of studies
We will use keywords to build a comprehensive search 
strategy that will be used to search the Cochrane Central 
Register of Controlled Trials, PubMed, EMBASE and 
Scopus for publications indexed from 1980 to July 2018. 
We have chosen to limit our search to this timeline as it 
corresponds to the identification of the first case of HIV. 
We have provided the proposed search strategy for one 
database, PubMed, in table 1. We will also search the 
WHO International Clinical Trials Registry Platform 
for ongoing studies and the reference lists of included 
studies and related reviews for other relevant studies. We 
will include trial reports available in English or French.
study selection
We will develop the search strategy and conduct the 
electronic searches with the help of an information 
specialist. The search output from the various databases 
will be combined and deduplicated using a reference 
management software (EndNote). Two authors will inde-
pendently screen the titles and abstracts obtained from 
the electronic searches to create a pool of potentially 
eligible studies. Disagreement between the two authors 
will be resolved by discussion and consensus, and a third 
author will arbitrate if discussions fail. We will obtain the 
full articles of the potentially eligible studies which two 
authors will independently scrutinise for relevance using 
a standardised eligibility form with predefined inclusion 
criteria. The criteria for relevance will be based on the 
study design, interventions, participants and outcomes. 
If some of the information needed to classify the study 
is missing, we will attempt to contact the study authors 
for clarification. In the event where the authors do not 
have the missing information, or fail to respond, the 
study will be classified as ‘awaiting assessment’. Disagree-
ments between the two authors will be resolved by discus-
sion and consensus. Should the disagreement persist, a 
third author will arbitrate. Following the eligibility assess-
ment, each study will be classified as included, excluded, 
ongoing or awaiting classification. A study that meets the 
design, intervention and participant criteria for which 
relevant outcomes are not yet available will be classified 
as ongoing (if the study is not yet completed) or awaiting 
classification (if already completed). We will prepare a 
table of the excluded studies, with reasons for exclusion. 
All four authors will take part in study selection.
data extraction
Two authors will independently extract data using a stan-
dard data extraction form. Extracted information will 
include study details such as location and setting, study 
design, population size and attrition rate; intervention 
details such as time period for the intervention and length 
of follow-up; comparator details including the type of 
comparator, time period for the comparator and length of 
follow-up; and outcome details such as HIV and STI inci-
dence (with types of laboratory tests used to confirm HIV 
and STI diagnosis), degree of compliance with female 
condom use, acceptability and adverse effects. Disagree-
ment between the two authors will be resolved by discus-
sion and consensus. Should the disagreement persist, 
a third author will arbitrate. Where information in the 
study report(s) is unclear or missing, we will contact the 
authors and request for the missing information. If the 
Table 1 Search strategy
Search Query
#1 Search (HIV Infections[MeSH] OR HIV[MeSH] 
OR hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR 
hiv1[tiab] OR hiv2[tiab] OR hiv infect*[tiab] OR 
HIV[tiab] OR human immunedeficiency virus[tiab] 
OR human immuno-deficiency virus[tiab] OR 
human immune-deficiency virus(tiab) OR ((human 
immun*[tiab]) AND (deficiency virus[tiab])) OR 
AIDS[tiab] OR acquired immunedeficiency 
syndrome[tiab] OR acquired immuno-deficiency 
syndrome[tiab] OR acquired immune-deficiency 
syndrome[tiab] OR ((acquired immun*[tiab]) AND 
(deficiency syndrome[tiab]))
#2 Search (sexually transmitted diseases[mh]) OR 
sexually transmitted diseases, viral[mh] OR 
sexually transmitted diseases, bacterial[mh] 
OR sexually transmitted disease*[tiab] OR 
venereal disease*[tiab] OR sexually transmissible 
disease*[tiab] OR sexually transmitted 
disorder*[tiab] OR sexually transmitted 
infection*[tiab] OR sexually transmitted infectious 
disease*(tiab) OR sexually transmissable 
disorder*[tiab] OR sti[tiab] OR std[tiab])
#3 Search (#1 OR #2)
#4 Search (randomized controlled trial [pt] OR 
controlled clinical trial [pt] OR randomized [tiab] 
OR placebo [tiab] OR drug therapy [sh] OR 
randomly [tiab] OR trial [tiab] OR groups [tiab]) 
NOT (animals [mh] NOT humans [mh])
#5 Search (condoms, female[mh] OR female 
condom[tiab] OR female condoms[tiab] OR 
(female[tiab] AND condom*[tiab]))
#6 Search (#3 AND #4 AND #5)
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authors fail to provide the missing information, the study 
will be included in the review; however, the findings that 
are unavailable will not be synthesised with findings from 
other included studies addressing the relevant outcome.
Assessing risk of bias
Two authors will independently assess the risk of bias 
in each included trial using the Cochrane risk of bias 
tool.26 This will include information on the adequacy of 
the generation of the allocation sequence and allocation 
concealment (for assessment of the risk of selection bias), 
blinding care providers (for performance bias), blinding 
of outcome assessors (for detection bias), completeness 
of outcome data (for attrition bias), completeness of 
outcome reporting (for reporting bias). Given the nature 
of the interventions considered in this review, the study 
participants cannot be blinded. The risk of performance 
bias will therefore be assessed based on whether the care 
providers were aware of the intervention or not.
data synthesis
We will use the Cochrane Review Manager for data 
analyses. We will express study results as risk ratios (for 
dichotomous variables such as HIV incidence) or mean 
differences (for continuous outcomes such as accept-
ability); with their 95% CIs. We will combine study results 
in a meta-analysis if included trials found are similar in 
terms of design, participants, interventions and outcomes.
We will assess heterogeneity between trial results by 
visually inspecting the forest plots to assess whether the 
CIs overlap, followed by a more formal test, that is, the 
χ2 test of homogeneity (with significance defined as an 
alpha level of 10%). We will also use the I2 test to quantify 
the degree of heterogeneity.
In the absence of significant statistical heterogeneity, 
we will pool the study results using the Mantel-Haenszel 
fixed-effect method. If we detect significant heteroge-
neity and consider it clinically meaningful to combine 
the trials, we will use the random-effects meta-analysis. 
We will explore the cause of observed heterogeneity 
using subgroup analyses, with subgroups defined by 
study design (randomised vs non-randomised trials), 
HIV status (for outcomes other than HIV acquisition), 
method of STI diagnosis (clinical vs laboratory), type 
of comparison intervention, trial duration, degree of 
compliance with female condom use and sample size. 
When a significant statistical association is found, we 
shall calculate the absolute risk reduction (or increase) 
with the number needed to treat or number needed 
to harm, as appropriate. Data obtained from studies 
that are not similar enough to be meta-analysed will be 
combined using narrative synthesis. We will use a funnel 
plot to asses for publication bias if we have more than 
10 included studies in a meta-analysis. Finally, we will 
assess the strength or certainty of the evidence using the 
Grading of Recommendations Assessment, Development 
and Evaluation approach which rates the certainty of 
evidence for each outcome by taking into consideration 
the risk of bias, directness of evidence, heterogeneity, 
precision and risk of publication bias.27
timeline for the systematic review
We registered the planned systematic review with the 
International Prospective Register of Systematic Reviews 
(PROSPERO) in March 2018.28 We plan to finalise the 
search strategy in August 2018, conduct the searches and 
select eligible studies between August and October 2018; 
and collect data, conduct statistical analyses, and prepare 
and submit the manuscript for consideration by a peer-re-
viewed journal between November 2018 and April 2019.
Ethics and dissemination
We will use data that are readily available in the public 
domain, hence no formal ethical approval is required for 
this review. The findings of this review will be presented 
at relevant conferences and published in a peer-reviewed 
journal. This protocol has been written following the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses Protocols guidelines,29 and the findings 
of this review and any amendments will be reported 
according to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses statement.30
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